Cystic Fibrosis

Top Story

Orkambi yields positive results in younger patients with cystic fibrosis

June 12, 2017

Orkambi improved lung function in patients 6 to 11 years old with cystic fibrosis within 15 days of treatment, according to phase 3 trial results recently published in The Lancet Respiratory Medicine. The findings were also presented at the European Cystic Fibrosis Society conference.

NIH data suggest that cystic fibrosis occurs in one in 2,500 to 3,500 white newborns and is less common in other ethnic groups, affecting about one in 17,000 blacks and one in 31,000 Asian Americans.

FDA News

FDA expands approval of Kalydeco to include additional cystic fibrosis mutations

May 18, 2017
The FDA has extended approval for ivacaftor to treat 23 additional mutations of cystic fibrosis among pediatric patients aged older than 2 years. Previously, ivacaftor…
In the Journals

Patients with cystic fibrosis live nearly 10 years longer in Canada than US

March 13, 2017
Compared with American patients with cystic fibrosis, Canadians with the disorder have a significant survival advantage, most likely due to differences in health care…
In the Journals

Antifibrotic drugs safe in idiopathic pulmonary fibrosis patients undergoing lung transplant

December 22, 2016
It is safe to administer antifibrotic drugs to patients with idiopathic pulmonary fibrosis, possibly reducing disease progression over time in those awaiting lung
More Headlines »
CME Article

Contact Dermatitis: From Basics to Allergodromes

Pediatric Annals, February 2009, Volume 38 Issue 2
Parents frequently bring their infants, toddlers, children and adolescents to see their pediatricians for various…
More »
Meeting News

VIDEO: Gefitinib may ‘change the paradigm’ to treat lung cancer

August 10, 2017
More »